Exposure to the electrofusion process can increase the immunogenicity of human cells

Cancer Immunology, Immunotherapy

Volumn 54, Issue 9, 2005, Pages 880-890

  Hock, Barry D ^a   Roberts, Georgina ^a   McKenzie, Judith L ^a   Gokhale, Prachee ^a   Salm, Nina ^a   McLellan, Alexander D ^a   Patton, Nigel W ^a   Roake, Justin A ^b  

^a UNIVERSITY OF OTAGO   (New Zealand)

^b CHRISTCHURCH HOSPITAL   (New Zealand)

Author keywords

Colorectal; Dendritic cell; Electrofusion; Hybrid; Tumour

Indexed keywords

CALCIUM DERIVATIVE; GAMMA INTERFERON; GLUCOSE; MAGNESIUM DERIVATIVE; TUMOR ANTIGEN;

APOPTOSIS; ARTICLE; BREAST CANCER; CELL CULTURE; CELL LINE; CELL TYPE; CONTROLLED STUDY; CYTOKINE RELEASE; CYTOTOXICITY; DENDRITIC CELL; ELECTROFUSION (CELL); EXPOSURE; HUMAN; HUMAN CELL; HYBRID; HYBRID CELL; IMMUNOGENICITY; IMMUNOSTIMULATION; NECROSIS; PERIPHERAL BLOOD MONONUCLEAR CELL; PHENOTYPE; PRIORITY JOURNAL; PROTEIN EXPRESSION; T LYMPHOCYTE; TUMOR CELL;

ANTIGEN-PRESENTING CELLS; ANTIGENS, NEOPLASM; APOPTOSIS; BREAST NEOPLASMS; CANCER VACCINES; CELL FUSION; CELL SURVIVAL; COLONIC NEOPLASMS; DENDRITIC CELLS; ELECTROPORATION; HUMANS; INTERFERON TYPE II; NECROSIS; T-LYMPHOCYTES, CYTOTOXIC; TUMOR CELLS, CULTURED;

EID: 22244458540     PISSN: 03407004     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00262-004-0659-9     Document Type: Article

References (44)

1. Scott-Taylor TH, Pettengell R, Clarke I, Stuhler G, La Barthe MC, Walden P, Dalgleish AG (2000) Human tumour and dendritic cell hybrids generated by electrofusion: potential for cancer vaccines. Biochim Biophys Acta 1 500:265-279
2. Shu S, Cohen P (2001) Tumor-dendritic cell fusion technology and immunotherapy strategies. J Immunother 24:99-100
3. Gong J, Chen D, Kashiwaba M, Kufe D (1997) Induction of antitumour activity by immunization with fusions of dendritic and carcinoma cells. Nat Med 3:558-561
4. Siders WM, Vergilis KL, Johnson C, Shields J, Kaplan JM (2003) Induction of specific antitumor immunity in the mouse with the electrofusion product of tumor cells and dendritic cells. Mol Ther 7:498-505
5. Zhang JK, Li J, Zhang J, Chen HB, Chen SB (2003) Antitumor immunopreventive and immunotherapeutic effect in mice induced by hybrid vaccine of dendritic cells and hepatocarcinoma in vivo. World J Gastroenterol 9:479-484
6. Wang J, Saffold S, Cao X, Krauss J, Chen W (1998) Eliciting T cell immunity against poorly immunogenic tumors by immunization with dendritic cell-tumor fusion vaccines. J Immunol 161:5516-5524
7. Orentas RJ, Schauer D, Bin Q, Johnson BD (2001) Electrofusion of a weakly immunogenic neuroblastoma with dendritic cells produces a tumor vaccine. Cell Immunol 213:4-13
8. Xia J, Tanaka Y, Koido S, Liu C, Mukherjee P, Gendler SJ, Gong J (2003) Prevention of spontaneous breast carcinoma by prophylactic vaccination with dendritic/tumor fusion cells. J Immunol 170:1980-1986
9. Lindner M, Schirrmacher V (2002) Tumour cell-dendritic cell fusion for cancer immunotherapy: comparison of therapeutic efficiency of polyethylen-glycol versus electro-fusion protocols. Eur J Clin Invest 32:207-217
10. Celluzzi CM, Falo LD, Jr. (1998) Physical interaction between dendritic cells and tumor cells results in an immunogen that induces protective and therapeutic tumor rejection. J Immunol 160:3081-3085
11. Li J, Holmes LM, Franek KJ, Burgin KE, Wagner TE, Wei Y (2001) Purified hybrid cells from dendritic cell and tumor cell fusions are superior activators of antitumor immunity. Cancer Immunol Immunother 50:456-462
12. Phan V, Errington F, Cheong SC, Kottke T, Gough M, Altmann S, Brandenburger A, Emery S, Strome S, Bateman A, Bonnotte B, Melcher A, Vile R (2003) A new genetic method to generate and isolate small, short-lived but highly potent dendritic cell-tumor cell hybrid vaccines. Nat Med 9:1215-1219
13. Lespagnard L, Mettens P, Verheyden AM, Tasiaux N, Thielemans K, van Meirvenne S, Geldhof A, De Baetselier P, Urbain J, Leo O, Moser M (1998) Dendritic cells fused with mastocytoma cells elicit therapeutic antitumor immunity. Int J Cancer 76:250-258
14. Gong J, Koido S, Chen D, Tanaka Y, Huang L, Avigan D, Anderson K, Ohno T, Kufe D (2002) Immunization against murine multiple myeloma with fusions of dendritic and plasmacytoma cells is potentiated by interleukin 12. Blood 99:2512-2517
15. Gong J, Chen D, Kashiwaba M, Li Y, Chen L, Takeuchi H, Qu H, Rowse GJ, Gendler SJ, Kufe D (1998) Reversal of tolerance to human MUC1 antigen in MUC1 transgenic mice immunized with fusions of dendritic and carcinoma cells. P Natl Acad Sci USA 95:6279-6283
16. Hayashi T, Tanaka H, Tanaka J, Wang R, Averbook BJ, Cohen PA, Shu S (2002) Immunogenicity and therapeutic efficacy of dendritic-tumor hybrid cells generated by electrofusion. Clin Immunol 104:14-20
17. Tanaka H, Shimizu K, Hayashi T, Shu S (2002) Therapeutic immune response induced by electrofusion of dendritic and tumor cells. Cell Immunol 220:1-12
18. Goddard RV, Prentice AG, Copplestone JA, Kaminski ER (2003) In vitro dendritic cell-induced T cell responses to B cell chronic lymphocytic leukaemia enhanced by IL-15 and dendritic cell-B-CLL electrofusion hybrids. Clin Exp Immunol 131:82-89
19. Gong J, Avigan D, Chen D, Wu Z, Koido S, Kashiwaba M, Kufe D (2000) Activation of antitumor cytotoxic T lymphocytes by fusions of human dendritic cells and breast carcinoma cells. P Natl Acad Sci USA 97:2715-2718
20. Gong J, Nikrui N, Chen D, Koido S, Wu Z, Tanaka Y, Cannistra S, Avigan D, Kufe D (2000) Fusions of human ovarian carcinoma cells with autologous or allogeneic dendritic cells induce antitumor immunity. The J Immunol 165:1705-1711
21. Soruri A, Fayyazi A, Neumann C, Schlott T, Jung T, Matthes C, Zwirner J, Riggert J, Peters JH (2001) Ex vivo generation of human anti-melanoma autologous cytolytic T cells by dentritic cell/melanoma cell hybridomas. Cancer Immunol Immunother 50:307-314
22. Chan RC, Xie H, Zhao GP, Xie Y (2002) Dendritomas formed by fusion of mature dendritic cells with allogenic human hepatocellular carcinoma cells activate autologous cytotoxic T lymphocytes. Immunol Lett 83:101-109
23. Gottfried E, Krieg R, Eichelberg C, Andreesen R, Mackensen A, Krause SW (2002) Characterization of cells prepared by dendritic cell-tumor cell fusion. Cancer Immun 2:15
24. Parkhurst MR, DePan C, Riley JP, Rosenberg SA, Shu S (2003) Hybrids of dendritic cells and tumor cells generated by electrofusion simultaneously present immunodominant epitopes from multiple human tumor-associated antigens in the context of MHC class I and class II molecules. J Immunol 170:5317-5325
25. Holmes LM, Li J, Sticca RP, Wagner TE, Wei Y (2001) A rapid, novel strategy to induce tumor cell-specific cytotoxic T lymphocyte responses using instant dendritomas. J Immunother 24:122-129
26. Trevor KT, Cover C, Ruiz YW, Akporiaye ET, Hersh EM, Landais D, Taylor RR, King AD, Walters RE (2004) Generation of dendritic cell-tumor cell hybrids by electrofusion for clinical vaccine application. Cancer Immunol Immunother 53:705-714
27. Trefzer U, Weingart G, Chen Y, Herberth G, Adrian K, Winter H, Audring H, Guo Y, Sterry W, Walden P (2000) Hybrid cell vaccination for cancer immune therapy: first clinical trial with metastatic melanoma. Int J Cancer 85:618-626
28. Krause SW, Neumann C, Soruri A, Mayer S, Peters JH, Andreesen R (2002) The treatment of patients with disseminated malignant melanoma by vaccination with autologous cell hybrids of tumor cells and dendritic cells. J Immunother 25:421-428
29. Kugler A, Stuhler G, Walden P, Zoller G, Zobywalski A, Brossart P, Trefzer U, Ullrich S, Muller CA, Becker V, Gross AJ, Hemmerlein B, Kanz L, Muller GA, Ringert RH (2000) Regression of human metastatic renal cell carcinoma after vaccination with tumor cell-dendritic cell hybrids. Nat Med 6:332-336
30. Marten A, Renoth S, Heinicke T, Albers P, Pauli A, Mey U, Caspari R, Flieger D, Hanfland P, Von Ruecker A, Eis-Hubinger AM, Muller S, Schwaner I, Lohmann U, Heylmann G, Sauerbruch T, Schmidt-Wolf IG (2003) Allogeneic dendritic cells fused with tumor cells: preclinical results and outcome of a clinical phase I/II trial in patients with metastatic renal cell carcinoma. Hum Gene Ther 14:483-494
31. Trefzer U, Herberth G, Wohlan K, Milling A, Thiemann M, Sherev T, Sparbier K, Sterry W, Walden P (2004) Vaccination with hybrids of tumor and dendritic cells induces tumor-specific T-cell and clinical responses in melanoma stage III and IV patients. Int J Cancer 110:730-740
32. Miley HE, Sheader EA, Brown PD, Best L (1997) Glucose-induced swelling in rat pancreatic beta-cells. J Physiol 504:191-198
33. Cortizo AM, Paladini A, Diaz GB, Garcia ME, Gagliardino JJ (1990) Changes induced by glucose in the plasma membrane properties of pancreatic islets. Mol Cell Endocrinol 71:49-54
34. Hock BD, Fearnley DB, Boyce A, McLellan AD, Sorg RV, Summers KL, Hart DNJ (1999) Human dendritic cells express a 95 kDa activation/differentiation antigen defined by CMRF-56. Tissue Antigens 53:320-334
35. Kotera Y, Shimizu K, Mule JJ (2001) Comparative analysis of necrotic and apoptotic tumor cells as a source of antigen(s) in dendritic cell-based immunization. Cancer Res 61:8105-8109
36. Neri S, Mariani E, Meneghetti A, Cattini L, Facchini A (2001) Calcein-acetyoxymethyl cytotoxicity assay: standardization of a method allowing additional analyses on recovered effector cells and supernatants. Clin Diagn Lab Immunol 8:1131-1135
37. Larsson M, Fonteneau JF, Bhardwaj N (2001) Dendritic cells resurrect antigens from dead cells. Trends Immunol 22:141-148
38. Feng H, Zeng Y, Graner MW, Katsanis E (2002) Stressed apoptotic tumor cells stimulate dendritic cells and induce specific cytotoxic T cells. Blood 100:4108-4115
39. Kleindienst P, Brocker T (2003) Endogenous dendritic cells are required for amplification of T cell responses induced by dendritic cell vaccines in vivo. J Immunol 170:2817-2823
40. Harshyne LA, Watkins SC, Gambotto A, Barratt-Boyes SM (2001) Dendritic cells acquire antigens from live cells for cross-presentation to CTL. J Immunol 166:3717-3723
41. Newton DA, Acierno PM, Metts MC, Baron PL, Brescia FJ, Gattoni-Celli S (2001) Semiallogeneic cancer vaccines formulated with granulocyte-macrophage colony-stimulating factor for patients with metastatic gastrointestinal adenocarcinomas: a pilot phase I study. J Immunother 24:19-26
42. Mattes J, Hulett M, Xie W, Hogan S, Rothenberg ME, Foster P, Parish C (2003) Immunotherapy of cytotoxic T cell-resistant tumors by T helper 2 cells: an eotaxin and STAT6-dependent process. J Exp Med 197:387-393
43. Westwood JA, Kelly JM, Tanner JE, Kershaw MH, Smyth MJ, Hayakawa Y (2004) Cutting Edge: Novel priming of tumor-specific immunity by NKG2D-triggered NK cell-mediated tumor rejection and Th1-independent CD4+ T cell pathway. J Immunol 172:757-761
44. Tsujimoto H, Nishizuka S, Redpath LJ, Stanbridge EJ (2001) Examination of the oncogenic potential of H19 gene in HeLa x normal human fibroblast hybrid cells. Int J Oncol 19:89-95